glp-1 drugs pharmaceutical companies 2025 Pipeline Update: August - Prime Therapeutics glp-1 drugs pharmaceutical companies partnerships

Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain

Using the same spot repeatedly causes lipodystrophy, a condition where subcutaneous fat thins or thickens at the injection site, altering absorption kinetics and potentially causing visible skin changes

doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

Samols graduated in medicine when he was just 21 years old and was one of a generation of migr scientists who left Apartheid South Africa

The hormone-aware metabolic framework presented here is an educational model designed to organize current knowledge about menopause physiology, metabolic regulation, and GLP-1 therapy